Early insurance coverage of elexacaftor/tezacaftor/ivacaftor for cystic fibrosis

Pediatr Pulmonol. 2021 Dec;56(12):4053-4054. doi: 10.1002/ppul.25659. Epub 2021 Sep 9.

Authors

Ashlee Anderson¹, Lindsey McCoy², Rebecca S Pettit³, Brittany A Wright⁴, Lisa Lubsch⁵

Affiliations

¹ Sanford Health, USA.
² Medical University of South Carolina, Charleston, South Carolina, USA.
³ Riley Hospital for Children at IU Health, Indianapolis, Indiana, USA.
⁴ University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
⁵ Southern Illinois University Edwardsville School of Pharmacy and SSM Health Cardinal Glennon Children's Hospital, Edwardsville, Illinois, USA.

PMID: 34499822
DOI: 10.1002/ppul.25659

No abstract available

Keywords: cystic fibrosis; insurance; medication access; pharmacy services; prior authorization.

Publication types

Letter

MeSH terms

Aminophenols / therapeutic use
Benzodioxoles / therapeutic use
Cystic Fibrosis Transmembrane Conductance Regulator / genetics
Cystic Fibrosis* / drug therapy
Humans
Indoles
Insurance Coverage
Pyrazoles
Pyridines
Pyrrolidines
Quinolones

Substances

Aminophenols
Benzodioxoles
Indoles
Pyrazoles
Pyridines
Pyrrolidines
Quinolones
tezacaftor
Cystic Fibrosis Transmembrane Conductance Regulator
ivacaftor
elexacaftor